Announcement • Jun 18
VitalHub UK Limited acquired Induction Healthcare Group PLC (AIM:INHC) from Harwood Capital LLP, Blue Muse Investments Pty Ltd and Lombard Odier Asset Management (Europe) Ltd. VitalHub UK Limited agreed to acquire Induction Healthcare Group PLC (AIM:INHC) from Harwood Capital LLP, Blue Muse Investments Pty Ltd, Lombard Odier Asset Management (Europe) Ltd, Hugo Stephenson and Other shareholders for £9.4 million on April 10, 2025. Under the terms of the Acquisition, each Induction shareholder will be entitled to receive £0.10 in cash for each Induction share held, valuing Induction at approximately £9.7 million. The Cash Consideration represents a premium of approximately 66.7% to the closing middle-market price of 6.0 pence per Induction Share on April 9, 2025. It is intended that the Acquisition shall be effected by means of a court-approved scheme of arrangement (the “Scheme”) under Part 26 of the Companies Act. The Scheme must be approved both by the Induction shareholders and the Court. In particular, the scheme of arrangement requires approval from Scheme shareholders who are on the register of members at the Voting Record Time and who constitute a majority in number of Scheme shareholders who vote at the Court Meeting representing at least 75% in value of the Scheme shares which are voted at the meeting.
The Induction Directors will unanimously recommend Induction shareholders to vote in favour of the Scheme. VitalHub has received irrevocable undertakings to vote in favour of the Scheme from the Induction Directors who hold Induction shares and certain institutional shareholders in respect of a total of 41,655,303 Induction shares, together representing approximately 44.3% of Induction’s issued ordinary share capital. The transaction is expected to close on or before July 31, 2025, with a long stop date of September 30, 2025. As on May 12, 2025, the board of Induction is pleased to announce that each of the resolutions posed at the Court Meeting and the General Meeting held earlier today in connection with the Acquisition were approved by the requisite majorities of Shareholders. As of June 4, 2025, the Secretary of State confirmed that no further action will be taken in relation to the Acquisition under the NSIA and therefore the NSIA Condition has now been satisfied. Induction and VitalHub are pleased to confirm that the Sanction Hearing, at which the Court will be asked to sanction the Scheme, is expected to take place on June 16, 2025. Subject to the Scheme receiving the sanction of the Court and the delivery of a copy of the Court Order to the Registrar of Companies, the Scheme is expected to become Effective on June 18, 2025. The long stop date is set for September 30, 2025.
Edwin Coe LLP acted as legal advisor for VitalHub UK Limited. Henrik Persson, Seamus Fricker and Elysia Bough of Cavendish Capital Markets Limited acted as financial advisor for VitalHub UK Limited. John McRoberts and Brandon Matthews of Aalto Capital LLP acted as financial advisor for Induction Healthcare Group PLC. Aalto Capital LLP acted as fairness opinion provider for Induction Healthcare Group PLC. Philip Davies, Oliver Platts and Patrick Weaver of Singer Capital Markets Advisory LLP acted as financial advisor for Induction Healthcare Group PLC. Burness Paull LLP acted as legal advisor for Induction Healthcare Group PLC.
VitalHub UK Limited completed the acquisition of Healthcare Group PLC (AIM:INHC) from Harwood Capital LLP, Blue Muse Investments Pty Ltd, Lombard Odier Asset Management (Europe) Ltd, Hugo Stephenson and Other shareholders on June 18, 2025. The members of the Induction Healthcare Group Board as detailed in the Scheme Document have resigned from the Induction Healthcare Group Board. Daniel Matlow, Brian Goffenberg and Michael Sanders have each been appointed as directors of Induction Healthcare Group . Induction Healthcare Group is now a wholly owned subsidiary of VitalHub UK Limited. Announcement • Jun 05
Induction Healthcare Group Expects Cancellation of Admission to Trading of its Shares on AIM Effective June 19, 2025 On 10 April 2025, the boards of Induction Healthcare Group PLC (‘Induction’) and VITALHUB UK LIMITED (‘Bidco’) announced that they had agreed the terms and conditions of a recommended cash acquisition pursuant to which Bidco shall acquire the entire issued, and to be issued, ordinary share capital of Induction (the ‘Acquisition’). The Acquisition is being implemented by means of a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the ‘Scheme’). On 17 April 2025, Induction published and posted a circular in relation to the Scheme (the ‘Scheme Document’) setting out, amongst other things, the full terms and conditions of the Scheme, an explanatory statement pursuant to section 897 of the Companies Act, an expected timetable of principal events, notices of the Court Meeting and General Meeting and details of the actions to be taken by Induction Shareholders. Expected Suspension of admission to trading of, and dealings in, Induction Shares By 7.30 a.m. on 18 June 2025. Effective Date of the Scheme is 18 June 2025(or, as soon as the Court Order has been delivered to the Registrar of Companies for registration), and expected Cancellation of admission to trading on AIM of Induction Shares By 7.30 a.m. on 19 June 2025. New Risk • May 25
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 9.1% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (UK£8.93m market cap, or US$12.1m). Announcement • Apr 11
VitalHub UK Limited agreed to acquire Induction Healthcare Group PLC (AIM:INHC) from Harwood Capital LLP, Blue Muse Investments Pty Ltd and Lombard Odier Asset Management (Europe) Ltd. on April 10, 2025. VitalHub UK Limited agreed to acquire Induction Healthcare Group PLC (AIM:INHC) from Harwood Capital LLP, Blue Muse Investments Pty Ltd, Lombard Odier Asset Management (Europe) Ltd, Hugo Stephenson and Other shareholders for approximately £9.41 million on April 10, 2025. Under the terms of the Acquisition, each Induction shareholder will be entitled to receive £0.10 in cash for each Induction share held, valuing Induction at approximately £9.7 million. The Cash Consideration represents a premium of approximately 66.7% to the closing middle-market price of 6.0 pence per Induction Share on 9 April 2025. It is intended that the Acquisition shall be effected by means of a court-approved scheme of arrangement (the “Scheme”) under Part 26 of the Companies Act. The Scheme must be approved both by the Induction shareholders and the Court. In particular, the scheme of arrangement requires approval from Scheme shareholders who are on the register of members at the Voting Record Time and who constitute a majority in number of Scheme shareholders who vote at the Court Meeting representing at least 75% in value of the Scheme shares which are voted at the meeting.
The Induction Directors will unanimously recommend Induction shareholders to vote in favour of the Scheme. VitalHub has received irrevocable undertakings to vote in favour of the Scheme from the Induction Directors who hold Induction shares and certain institutional shareholders in respect of a total of 41,655,303 Induction shares, together representing approximately 44.3% of Induction’s issued ordinary share capital. The transaction is expected to close on or before July 31, 2025, with a long stop date of September 30, 2025.
Edwin Coe LLP acted as legal advisor for VitalHub UK Limited. Henrik Persson, Seamus Fricker and Elysia Bough of Cavendish Capital Markets Limited acted as financial advisor for VitalHub UK Limited. John McRoberts and Brandon Matthews of Aalto Capital LLP acted as financial advisor for Induction Healthcare Group PLC. Aalto Capital LLP acted as fairness opinion provider for Induction Healthcare Group PLC. Philip Davies, Oliver Platts and Patrick Weaver of Singer Capital Markets Advisory LLP acted as financial advisor for Induction Healthcare Group PLC. Burness Paull LLP acted as legal advisor for Induction Healthcare Group PLC. New Risk • Apr 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 5.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (5.8% average weekly change). Earnings have declined by 9.1% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£5.63m market cap, or US$7.27m). Board Change • Apr 10
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Independent Non-Executive Director Jane Silber is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 10
Induction Healthcare Announces the Resignation of Andy Williams as Non-Executive Director Induction Healthcare announced that Andy Williams has submitted his resignation to the Board, stepping down from his position as Non-Executive Director and member of the Audit, Remuneration, and Nomination Committees of the Board with immediate effect. New Risk • Jan 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.98m (US$9.81m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 9.1% per year over the past 5 years. Market cap is less than US$10m (UK£7.98m market cap, or US$9.81m). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Announcement • Oct 30
Induction Healthcare Group PLC to Report First Half, 2025 Results on Nov 05, 2024 Induction Healthcare Group PLC announced that they will report first half, 2025 results on Nov 05, 2024 New Risk • Sep 10
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.04m (US$9.21m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 25% per year over the past 5 years. Market cap is less than US$10m (UK£7.04m market cap, or US$9.21m). Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change). Announcement • Jul 05
Induction Healthcare Group PLC, Annual General Meeting, Aug 13, 2024 Induction Healthcare Group PLC, Annual General Meeting, Aug 13, 2024. Reported Earnings • Jul 05
Full year 2024 earnings released: UK£0.035 loss per share (vs UK£0.18 loss in FY 2023) Full year 2024 results: UK£0.035 loss per share (improved from UK£0.18 loss in FY 2023). Revenue: UK£13.6m (up 5.9% from FY 2023). Net loss: UK£3.25m (loss narrowed 80% from FY 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • Jul 02
Eolas Medical Ltd acquired Horizon Strategic Partners Ltd from Induction Healthcare Group PLC (AIM:INHC) for £1.2 million. Eolas Medical Ltd acquired Horizon Strategic Partners Ltd from Induction Healthcare Group PLC (AIM:INHC) for £1.2 million on July 1, 2024. The total consideration of £1.2 million comprises of £0.4 million will be paid in cash and £0.8 million will be deemed to be paid to Induction and immediately advanced to Eolas as a loan pursuant to a convertible loan agreement between Induction and Eolas, with a maturity date of 31 May 2027. In certain circumstances, Induction can, inter alia, either require full repayment of the Loan or convert the Loan into ordinary equity in Eolas.
As of September 30, 2023, Horizon Strategic Partners Ltd reported net assets of £1.2 million.
Philip Davies, Alaina Wong of Singer Capital Markets Limited acted as financial advisors to Induction Healthcare Group PLC.
Eolas Medical Ltd completed the acquisition of Horizon Strategic Partners Ltd from Induction Healthcare Group PLC (AIM:INHC) on July 1, 2024. New Risk • May 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 35% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (UK£11.5m market cap, or US$14.7m). Announcement • Apr 30
Induction Healthcare Group PLC to Report Fiscal Year 2024 Results on Jul 01, 2024 Induction Healthcare Group PLC announced that they will report fiscal year 2024 results on Jul 01, 2024 Reported Earnings • Nov 08
First half 2024 earnings released: UK£0.03 loss per share (vs UK£0.066 loss in 1H 2023) First half 2024 results: UK£0.03 loss per share (improved from UK£0.066 loss in 1H 2023). Revenue: UK£6.06m (down 15% from 1H 2023). Net loss: UK£2.42m (loss narrowed 50% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. New Risk • Oct 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.6m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 37% per year over the past 5 years. Minor Risk Market cap is less than US$100m (UK£26.2m market cap, or US$31.9m). New Risk • Aug 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£3.6m free cash flow). Earnings have declined by 37% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (UK£19.8m market cap, or US$25.2m). Reported Earnings • Jul 31
Full year 2023 earnings released: UK£0.18 loss per share (vs UK£0.10 loss in FY 2022) Full year 2023 results: UK£0.18 loss per share (further deteriorated from UK£0.10 loss in FY 2022). Revenue: UK£12.9m (up 63% from FY 2022). Net loss: UK£16.6m (loss widened 97% from FY 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings. Announcement • Jul 01
An Unknown buyer acquired Induction Switch from Induction Healthcare Group PLC (AIM:INHC). An Unknown buyer acquired Induction Switch from Induction Healthcare Group PLC (AIM:INHC) in March 31, 2023.An Unknown buyer completed the acquisition of Induction Switch from Induction Healthcare Group PLC (AIM:INHC) in March 31, 2023. New Risk • Jun 08
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (UK£22.1m market cap, or US$27.7m). Price Target Changed • May 09
Price target decreased by 36% to UK£0.49 Down from UK£0.77, the current price target is provided by 1 analyst. New target price is 128% above last closing price of UK£0.21. Stock is down 61% over the past year. The company posted a net loss per share of UK£0.10 last year. Announcement • Dec 20
Induction Healthcare Group PLC, Annual General Meeting, Jan 11, 2023 Induction Healthcare Group PLC, Annual General Meeting, Jan 11, 2023, at 09:30 Coordinated Universal Time. Location: 50 Liverpool Street, London EC2M 7PY London United Kingdom Reported Earnings • Nov 29
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: UK£0.10 loss per share. Revenue: UK£7.91m (up 423% from FY 2021). Net loss: UK£8.43m (loss widened 11% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.9%. Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 8.5% growth forecast for the Healthcare Services industry in the United Kingdom. Announcement • Nov 29
Induction Healthcare Group PLC to Report First Half, 2023 Results on Dec 05, 2022 Induction Healthcare Group PLC announced that they will report first half, 2023 results on Dec 05, 2022 Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Leslie-Ann Reed was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 26
Induction Healthcare Group PLC to Report Fiscal Year 2022 Final Results on Nov 28, 2022 Induction Healthcare Group PLC announced that they will report fiscal year 2022 final results on Nov 28, 2022 Board Change • Jun 09
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Director Leslie-Ann Reed was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jun 07
Induction Announces Directorate Change Induction announced that Christopher Samler has been appointed as Non-Executive Chairman. Christopher takes over from Chris Spencer, with immediate effect, after an externally facilitated recruitment process. Christopher started his career in the British Army before joining The Boston Consulting Group as an analyst which led to a variety of senior general management positions at Baxter International, the US-based healthcare multinational. Subsequently, Christopher was Chief Executive Officer of a series of fast-growing venture capital backed healthcare businesses including Imutran Ltd. and Weston Medical plc, the latter of which he took through three venture capital funding rounds to an IPO on the Main Market of the London Stock Exchange in 2000. Board Change • May 31
High number of new directors Non-Executive Director Andy Williams was the last director to join the board, commencing their role in 2020. Announcement • May 04
Induction Healthcare Announces Dr. Hugo Stephenson Stand Down from His Position as Group Executive Director Induction Healthcare announced that Dr. Hugo Stephenson, who is based in Australia, will stand down from his position as Group Executive Director, after seeing priority ambitions for the Group realised during the period of pandemic restrictions, and return to the Non-executive Director role he originally held on admission to AIM in May 2019. Board Change • Apr 27
High number of new directors Non-Executive Director Andy Williams was the last director to join the board, commencing their role in 2020. Recent Insider Transactions • Apr 14
Non-Executive Director recently bought UK£100k worth of stock On the 11th of April, Andrew Williams bought around 191k shares on-market at roughly UK£0.52 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£256k more in shares than they have sold in the last 12 months. Reported Earnings • Dec 03
First half 2022 earnings: EPS in line with expectations, revenues disappoint First half 2022 results: UK£0.082 loss per share (up from UK£0.085 loss in 1H 2021). Revenue: UK£4.59m (up UK£4.01m from 1H 2021). Net loss: UK£6.00m (loss widened 89% from 1H 2021). Revenue missed analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 167%, compared to a 415% growth forecast for the industry in the United Kingdom. Announcement • Jun 09
Induction Healthcare Group PLC (AIM:INHC) completed the acquisition of Attend Anywhere Limited. Induction Healthcare Group PLC (AIM:INHC) entered into a conditional share purchase agreement to acquire Attend Anywhere Limited from A.C.N. 167 231 307 Pty Ltd and Chris Ryan for £29.4 million on May 21, 2021. Under the terms, Induction will pay £12.6 million cash plus £0.8 million and will issue 14.3 million shares . Chris Ryan, Attend Anywhere's CEO, will join the Company's executive management team and will hold 11 million Shares. Part of the proceeds of the Placing will be used to fund the Cash Consideration in respect of the Acquisition. The pro forma summary unaudited management accounts of Attend Anywhere for the 12 months ended March 31, 2021 showed revenue of £9.7 million and EBITDA of £3.3 million. Transaction is conditional upon the approval by Shareholders, Admission of the Placing Shares and dispatching of Circular. The Board considers Attend Anywhere to be a clear strategic fit with Induction and believes the Acquisition will provide a number of commercial, operational and financial benefits, which are expected to create value for Shareholders. Transaction is expected to close on June 9, 2021. Philip Davies and Kailey Aliyar of N+1 Singer acted as nominated advisors and broker for Induction. KPMG Corporate Finance LLC acted as financial advisor to Attend Anywhere Limited.
Induction Healthcare Group PLC (AIM:INHC) completed the acquisition of Attend Anywhere Limited on June 9, 2021. Announcement • May 22
Induction Healthcare Group PLC (AIM:INHC) entered into a conditional share purchase agreement to acquire Attend Anywhere Limited from A.C.N. 167 231 307 Pty Ltd and Chris Ryan for £29.4 million. Induction Healthcare Group PLC (AIM:INHC) entered into a conditional share purchase agreement to acquire Attend Anywhere Limited from A.C.N. 167 231 307 Pty Ltd and Chris Ryan for £29.4 million on May 21, 2021. Under the terms, Induction will pay £12.6 million cash plus £0.8 million and will issue 14.3 million shares . Chris Ryan, Attend Anywhere's CEO, will join the Company's executive management team and will hold 11 million Shares. Part of the proceeds of the Placing will be used to fund the Cash Consideration in respect of the Acquisition. The pro forma summary unaudited management accounts of Attend Anywhere for the 12 months ended March 31, 2021 showed revenue of £9.7 million and EBITDA of £3.3 million. Transaction is conditional upon the approval by Shareholders, Admission of the Placing Shares and dispatching of Circular. The Board considers Attend Anywhere to be a clear strategic fit with Induction and believes the Acquisition will provide a number of commercial, operational and financial benefits, which are expected to create value for Shareholders. Transaction is expected to close on June 9, 2021. Philip Davies and Kailey Aliyar of N+1 Singer acted as nominated advisors and broker for Induction. Announcement • Mar 16
Induction Healthcare Group plc Announces Contract Wins for Induction Booking Induction Healthcare announces commercial contract wins with Sussex Community NHS Foundation Trust and East & North Hertfordshire NHS Trust, to enlist Induction Booking, an appointment booking service, to aid coordination of COVID-19 vaccination and follow-up appointments. These new contracts provide further revenue and commercial momentum for Induction. The current financial year, ending 31 March 2021, will see the first full year of revenue contribution from Induction's digital product platform. The Company has been building a strong momentum in sales and annual recurring revenues across all of its subscription-based software products and has a strong pipeline of orders with multi-year contracts. Announcement • Mar 09
Induction Healthcare Announces Two New Public Sector and Academic Contracts with the University of the West of England and South Gloucestershire Council Induction Healthcare announced two new public sector and academic contracts with the University of the West of England and South Gloucestershire Council, for Induction Booking to enable the booking of COVID-19 lateral flow tests. These contracts reflect the expanded use of Induction Booking outside of its core NHS hospital appointment bookings and into local government and academic institution deployment. Universities are undertaking greater efforts to identify students who may have Coronavirus and be infectious to others despite showing no symptoms. Induction Booking will facilitate appointments for COVID-19 lateral flow tests. By taking a test, it will allow students to return home between terms and help to stop the spread of the virus, protecting other people and saving lives. The new contracts will provide further strong revenue and commercial momentum for Induction and exemplify how the Company's range of products can be utilised among wider markets to help simplify the booking process in the UK's COVID-19 testing efforts. Is New 90 Day High Low • Mar 07
New 90-day high: UK£0.81 The company is up 5.0% from its price of UK£0.78 on 07 December 2020. The British market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare Services industry, which is up 17% over the same period. Announcement • Jan 13
Royal Free London NHS Foundation Trust Selects Induction to Deliver Patient Portal Induction announced a contract with the Royal Free London NHS Foundation Trust ("RFL"). Induction Zesty, a leading provider of patient portals to NHS Hospitals, has delivered the My RFL Care patient portal as the first phase of an ambitious roadmap for RFL's digital patient services in the next two years. The My RFL Care portal launched in August 2020 and has had significant traction with over 50,000 patients registering and using the service in the first few months. 250,000 patients are expected to adopt the service in the first year. The RFL combines globally recognised clinical expertise with local and friendly hospital care to represent the best of the NHS. The trust is a world-leader in a range of specialist services, including infectious diseases, immunology, kidney and liver transplantation, cancer care, plastic surgery and vascular surgery. The trust also runs internationally recognised clinical research programmes and is a leading teaching hospital. Induction Zesty are committed to transforming clinical pathways in acute hospitals by putting the right technology in the hands of the patient. This patient-centric, technology-driven vision delivers superior patient outcomes while reducing whole-system costs for hospitals. It alleviates the strain on hospital resources and embeds a long-term foundation for future improvements. Is New 90 Day High Low • Dec 23
New 90-day low: UK£0.74 The company is down 1.0% from its price of UK£0.74 on 24 September 2020. The British market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 17% over the same period. Is New 90 Day High Low • Nov 11
New 90-day high: UK£0.97 The company is up 2.0% from its price of UK£0.95 on 12 August 2020. The British market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is down 1.0% over the same period. Announcement • Aug 02
Induction Healthcare Group PLC to Report Fiscal Year 2020 Results on Aug 06, 2020 Induction Healthcare Group PLC announced that they will report fiscal year 2020 results on Aug 06, 2020 Announcement • Jul 30
Induction Healthcare Group PLC (AIM:INHC) completed the acquisition of Zesty Limited from James Balmain and others. Induction Healthcare Group PLC (AIM:INHC) entered into conditional share purchase agreement to acquire Zesty Limited from James Balmain and others for £12.7 million on May 18, 2020. Under the terms of the transaction, Induction Healthcare will pay £0.5 million in cash plus the issue of 12,424,527 new ordinary shares. The issue of the new shares is conditional, inter alia, upon the approval by shareholders of the resolutions to be sought at the general meeting convened for June 5, 2020. On completion of the acquisition, Zesty will become a wholly owned subsidiary of the Induction Healthcare. James Balmain will be appointed to the position of Joint-Chief Executive Officer of the Induction Healthcare Group, a role that will be shared with Hugo Stephenson, current Chief Executive Officer. Andrew Williams will be appointed to the Induction Board at completion of the acquisition. On or shortly following completion of the acquisition, it is anticipated that Ibraheem Mahmood will step down from the Board of Directors of Induction Healthcare. However, he will continue in a business development role. Services Innovants Santé Autonomie, FPCI and Andrew Goodwin each is entitled to appoint a person to be an observer at meetings of the Board. This transaction is conditional upon despatch of circular to shareholders, shareholders approving the resolutions to be proposed at the general meeting, the exercise and / or waiver and / or lapse in full of all of the existing share options granted to employees of Zesty and the allotment and issue by Zesty of ordinary shares in the capital of Zesty pursuant to the relevant exercised share options and the conversion in full of certain shareholder loans made by certain shareholders in Zesty. The Directors of Induction Healthcare unanimously recommend that shareholders vote in favour of the resolutions to be proposed at the general meeting. And it is expected that completion of the acquisition will take place on June 8, 2020 and that admission of the new ordinary shares will take place on or about June 9, 2020. James Black, Freddie Barnfield, Huw Jeremy and Matthew Jones of Numis Securities Limited acted as a financial advisor to Induction Healthcare Group.
Induction Healthcare Group PLC (AIM:INHC) completed the acquisition of Zesty Limited from James Balmain and others on June 9, 2020.